As a recent spinout from Stanford, Cephla offers scalable microscopy/imaging systems and solutions that give users the best of three worlds: access to latest technologies and application specific optimizations from bespoke setups, flexibility of high-end research microscopes, and throughput and robustness of high content screening systems. In addition, our open-source and python based software that gives users total control simplifies integrations and creations of complex workflows. Currently covering live cell imaging, organoid, cell painting, optical pooled screens, spatial omics and expansion microscopy, Cephla is excited about scaling users’ data production capabilities and helping users with their lab in a loop implementations.
Cellular Technology Limited (C.T.L.)
Cellular Technology Limited, (CTL) is a leading solution provider for immune monitoring supporting both research, pre-clinical and clinical studies phase I, II, III, IV and commercial. We help you to get the best possible, most reliable results, by offering a wide range of products and services, including: CONTRACT LABORATORY SERVICES: Our CLEP/CLIA-certified laboratory can provide logistics (USA as well as globally), cryopreservation of functional PBMC from whole blood (serves as central blood processing laboratory in North America), ELISPOT, ELISA, NAb, multiplex Cytokine Bead Arrays (CBA), Flow Cytometry (phenotyping, ICS, multimer readouts etc.), Killer assays, MAT and more. CTL is developing, validating and performing low and high-throughput format testing, tailored to our clients’ needs. INSTRUMENTATION: Image analyzers (ImmunoSpot®), high-throughput Analysis/Counting: ELISPOT, FluoroSpot, NK Assays, Viral Plaque (PRNT, FRNT, FFA), Bactericidal, Microbial Colony Counting, Genotoxic (MLA, AMES), Yeast Viability analysis, Stem Cell Assays and more…. CONSUMABLES: Cryopreserved functional PBMC: Over 150 HLA-typed donors with established reactivity to TH1/Th2 analytes to HLA Class I & Class II-restricted antigens. B and T Cell ELISPOT Kits to multiple species, FluoroSpot Kits ranging from single to multiplexed 4-color analytes and serum-free media, cryopreservation standardization solutions for functional PBMC generation and more…
CELLTREAT Scientific Products
CELLTREAT Scientific Products is a manufacturer of cell culture consumables and liquid handling instruments. CELLTREAT Scientific Products has a long-standing history of innovative design, developing an optimized user experience at an affordable price – the ultimate in ergonomics and productivity.
Bruker Spatial Biology
Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial molecular biology solutions, including instruments, assays, software, and services to support life sciences research. By integrating technologies from NanoString and Canopy Biosciences, Bruker offers an extensive portfolio designed to meet the diverse needs of global researchers exploring spatial biology. The CosMx® Spatial Molecular Imager (SMI) enables high-plex detection and analysis of over 6,000 RNAs with single-cell resolution and precise cell segmentation, supported by the cloud-based AtoMx™ Spatial Informatics Platform. The GeoMx® Digital Spatial Profiler is a leading platform for whole-tissue exploration, providing whole transcriptomics and high-plex proteomic readouts. The CellScape™ Precise Spatial Proteomics platform allows for high-plex protein expression analysis at single-cell resolution, using versatile, open-sourced reagents. The nCounter® Analysis System enables rapid quantification of profiling of gene and miRNA expression with high sensitivity. Together, Bruker Spatial Biology’s solutions are supported by a strong team of scientists, sales, and service associates, along with Canopy Multiomic Services for biopharmaceutical research, assay development, and clinical sample testing.
Bruker Advanced Imaging & 4D-Proteomics
Bruker Preclinical Imaging stands at the forefront of advanced imaging solutions for preclinical research, offering a cutting-edge portfolio that includes MRI, MPI, Micro-CT, Molecular Imaging (MOLECUBES, PET/SPECT/CT), and Optical Imaging (Spectral Instruments Imaging, BLI/FLI/X-Ray). These technologies drive scientific discovery and therapeutic development across oncology, neurology, cardiology, inflammation, infectious diseases, and more. Specializing in small animal imaging, Bruker provides researchers with precise insights into biological processes.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
BioMetas
Based in Shanghai with a presence in Boston, Massachusetts, BioMetas leverages decades of expertise to provide robust biological assays for pharmaceutical and biotech companies. With a strong foundation in CRO and early-discovery services, our customer-first approach ensures high-quality data delivered with rapid turnaround times. Through our validated in vitro and in vivo biological assays, we support the advancement of therapies that advance your discovery programs forward. BioMetas is dedicated to supporting your project team, saving you time to focus on discovering therapeutic agents that benefit patient communities.
Biolight Biotechnology Co., Ltd
We provide a series of professional, optical imaging instruments. Our technology focuses on the development of high efficiency reception and recognition technology for photon signals. The technology has many applications, ranging from life science research to, environmental quality monitoring and medical diagnostic services.
bioGenous Biotechnology, Inc
bioGenous is deeply committed to advancing foundational technological innovations in the organoid industry. It possesses globally leading, self-developed intellectual property in organoids and disease models, along with a GMP pharmaceutical-grade production technology system. Its main products include organoid culture reagents covering 23 types of normal tissues and 18 types of tumors, intelligent scenario-based equipment supporting the whole process of organoid construction, culture, and detection across multiple stages, and a flexible CRDMO technology platform tailored for pharmaceutical clients. Upholding the corporate vision of “Pioneering Pharmaceutical Innovation, Sharing Model Value,” bioGenous is dedicated to providing standardized, pharmaceutical-grade upstream organoid solutions for the global biopharmaceutical industry. To date, it has served over 500 advanced international and domestic innovative pharmaceutical companies, research institutions, and medical organizations. Its products are exported to Europe and the United States, with cumulative sales exceeding one billion units. The group’s headquarters is located in Yangpu District, Shanghai, with R&D centers in Shanghai, Hong Kong, and Cambridge, UK. It has established branches and subsidiaries in multiple cities, including Beijing, Guangzhou, Wuhan, Nanjing, Suzhou (technical service base), Dezhou (northern production base), Nanchang, and Tianjin. The company has received strategic investments from AstraZeneca and the SDIC Fund. Today, leveraging deep organoid resource
BIOEMTECH
BIOEMTECH’s mission and passion is accelerating preclinical research of promising drugs, towards clinical translation, through high quality services and products. BIOEMTECH offers boutique laboratories for evaluating new compounds in all stages of preclinical testing and has developed the eyes™ desktop cameras for real-time in vivo imaging of radionuclides and dyes. The eyes™ also allow for in vivo imaging of alpha emitters (212Pb & 225Ac) in oncological models and short scanning times. Both in BIOEMTECH’s services and products, fast screening applications are a core company value towards accelerating drug development.